Reyataz combination approved for treatment-naïve HIV

Bristol-Myer Squibb’s Reyataz (atazanavir sulfate capsules) has been approved for use in combination with ritonavir for treatment-naive adults infected with HIV-1. This approval was based on 883 patients in the open-label, randomized CASTLE study that showed Reyataz/ritonavir has similar antiviral efficacy to lopinavir/ritonavir combination therapy in adult patients not previously treated for HIV-1.

Reyataz is already approved for use with ritonavir, efavirenz and tenofovir in HIV-1 infection in treatment-experienced adults or monotherapy of treatment-naive adults and is available in 100mg, 150mg, 200mg, and 300mg dosage strengths.

For more information call (800) 332-2056 or visit